Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Arlene Martínez-RiveraDivision of Pediatric Neurology, Department of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0002-4180-1635
Robert N FetchoFeil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10065, USA.
Lizzie BirminghamDepartment of Psychology and Neuroscience Program, Temple University, Philadelphia, PA 19122, USA.
Jin XuDepartment of Anesthesiology, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.
Ruirong YangDepartment of Psychiatry, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0002-7507-5467
Careen FoordFeil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10065, USA.
Diego Scala-ChávezDivision of Pediatric Neurology, Department of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA.
Narmin MekawyDivision of Pediatric Neurology, Department of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0002-4629-6156
Kristen PleilDepartment of Pharmacology, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0001-6300-9414
Virginia M PickelFeil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0001-9374-724X
Conor ListonFeil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0002-1639-5401
Carlos M CastorenaCenter for Hypothalamic Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Joshua LevitzDepartment of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0002-8169-6323
Ying-Xian PanDepartment of Anesthesiology, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.ORCID 0000-0002-4006-8304
Lisa A BriandDepartment of Psychology and Neuroscience Program, Temple University, Philadelphia, PA 19122, USA.ORCID 0000-0002-1228-5061
Anjali M RajadhyakshaDivision of Pediatric Neurology, Department of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0002-8399-5466
Francis S LeeFeil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0002-7108-9650
Funding
Regulation of prefrontal cortical circuit function and reward-seeking behavior by stress-induced dendritic spine remodelingR01MH118451 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI Joshua Levitz, Conor M Liston · 2019 to 2026
$5.5M
Circuit and Synaptic Mechanisms of Endocannabinoid-Opioid CrosstalkR01DA054368 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Francis Sang Yong Lee, Anjali M Rajadhyaksha · 2022 to 2026
$3.5M
Molecular and circuit defects underlying different SCN2A mutations and ASDsR01MH118934 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI PITT, GEOFFREY S · 2019 to 2023
$3.2M
Sex Differences In Stress Inoculation Of Addiction-Like PhenotypesR01DA049837 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI BANGASSER, DEBRA A · 2020 to 2024
$3.1M
Impact of BDNF on the Development of Social Behavior CircuitsR01MH123154 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEE, FRANCIS SANG YONG, LISTON, CONOR M · 2020 to 2024
$3.0M
Prefrontal Cortical Microcircuit Mechanisms of Working Memory Deficits in Chronic StressR01MH109685 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI LISTON, CONOR M · 2016 to 2020
$2.8M
Investigating the mechanistic contribution of Cav1.2 channels in extinction of cocaine-associated memoriesR01DA053261 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Anjali M Rajadhyaksha · 2022 to 2026
$2.6M
Examining Mechanisms Underlying Drug-Associated Memory Erasure by Zeta-Inhibitory PeptideR01DA047265 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI BRIAND, LISA A · 2019 to 2023
$2.4M
Diagnostic and prognostic biomarkers for subtypes of addiction-related circuit dysfunctionR01DA047851 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI GOLDSTEIN, RITA Z, LISTON, CONOR M · 2019 to 2022
$2.4M
GABAergic Interneuron Dysfunction in Developing Cortical Circuits Underlying Autism Spectrum DisordersR01MH125006 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI DE MARCO GARCIA, NATALIA VANESA, RAJADHYAKSHA, ANJALI M · 2021 to 2025
$2.1M
The Role of Cav1.2 L-type Ca2+ Channels in Cocaine-Induced ReinstatementR01DA029122 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI RAJADHYAKSHA, ANJALI M · 2012 to 2016
$2.1M
L-Type Calcium Channel Mechanisms Mediating Comorbid Substance Use and Mood DisordersR01DA050454 · NIDA · YALE UNIVERSITY · PI ADDY, NII A · 2020 to 2024
Converging findings have established that the endocannabinoid (eCB) system serves as a possible target for the development of new treatments as a complement to opioid-based treatments. Here, we show in male and female mice that enhancing levels of the eCB, 2-arachidonoylglycerol (2-AG), through pharmacological inhibition of its catabolic enzyme, monoacylglycerol lipase (MAGL), either systemically or in the ventral tegmental area (VTA) with JZL184, leads to a substantial attenuation of the rewarding effects of opioids in mice using conditioned place preference and self-administration paradigms, without altering their analgesic properties. These effects are driven by cannabinoid receptor 1 (CB1R) within the VTA, as VTA CB1R conditional knockout counteracts JZL184's effects. Using fiber photometry with fluorescent sensors for calcium and dopamine (DA), we find that enhancing 2-AG levels diminishes opioid reward-related nucleus accumbens (NAc) activity and DA neurotransmission. Together, these findings reveal that 2-AG diminishes the rewarding properties of opioids and provides a potential adjunctive therapeutic strategy for opioid-related analgesic treatments.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia. · full record | OpenQuestion